search
Back to results

Proteus Sustained Behavior Change Study

Primary Purpose

Type 2 Diabetes Mellitus

Status
Withdrawn
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Proteus Sustained Behavior Change system
Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Sponsored by
Proteus Digital Health, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type 2 Diabetes Mellitus

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Self-reported diagnosis of Type 2 Diabetes Mellitus within the past 2-12 months
  • Hemoglobin A1c ≥7.5 and ≤11, obtained with the point-of-care HbA1c diagnostic device during the enrollment visit
  • Self-reported current use of metformin for Type 2 diabetes
  • Male or female ≥ 18
  • Outpatient
  • Self-reported capacity to perform "moderate" exercise, as specified by in the 2010 joint American College of Sports Medicine/American Diabetes Association guidelines
  • Designation of one caregiver to be involved in the study for its entire duration. A caregiver can be a relative, friend, or trained or untrained hired individual.
  • Self-reported mobile phone reception at home and/or at work
  • Willingness to adhere to study procedures, including troubleshooting of the Raisin System by a third-party if needed. The third party will be blinded to any personal subject identifiers.
  • Capacity to read and speak English proficiently, as judged by the investigator during the screening interview
  • Capacity to understand the instructions for the study, as judged by the investigator during the screening interview

Exclusion Criteria:

  • Self-reported treatment with metformin for less than 2 months at the time of screening
  • Self-reported adverse reaction to metformin (e.g., ongoing nausea, vomiting, bloating, diarrhea) or to other concomitant medications being administered at the time of screening
  • Self-reported use of injectable hypoglycemic agents, such as insulin, exenatide, liraglutide or pramlintide
  • Physical or medical condition that could prevent safe participation in moderate levels of physical activity, as surveyed by the Physical Activity Readiness Questionnaire (PAR-Q) and interpreted by the investigator
  • Inability to use a mobile phone (e.g., to find icons or to open and to read a SMS), or inability to operate the approved glucometer that will be provided for use in the study
  • Self-reported current (i.e., in the last 12 months) alcohol or drug abuse (including, but not limited, to use of marijuana)
  • Positive urine pregnancy test for women
  • Women of child bearing potential who are not using a medically accepted means of contraception. Accepted means of contraception include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy
  • Self-reported history of myocardial infarction within past 60 days
  • Self-reported history of cerebral vascular accident within past 60 days
  • Self-reported history of skin sensitivity to adhesive medical tape or metals
  • Self-reported history of acute or chronic dermatitis, excluding atopic dermatitis
  • Self-reported allergies that could preclude safe participation in the study
  • Current participation in another clinical study, or participation in a clinical study in the past 30 days during which an investigational device or drug was used
  • Any condition that, in the investigator's opinion, would preclude the subject's being able to meet all of the protocol requirements, or would compromise the subject's safety during participation in the study
  • Presence of cognitive impairment, as judged by the investigator during the screening interview
  • Inability to provide informed consent for any reason

Sites / Locations

  • Northwestern University
  • Center for Connected Health, Partners Healthcare

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Sustained Behavior Change system support

Control

Arm Description

Outcomes

Primary Outcome Measures

Self-efficacy
As measured by the 13-item self-efficacy expectancies and outcomes expectancies sub-scale of the Multidimensional Diabetes Questionnaire

Secondary Outcome Measures

Perceived effectiveness of caregiver support
As measured by the 12-item positive reinforcing behaviors and misguided support sub-scale of the Multidimensional Diabetes Questionnaire
Diabetes-related distress
As measured by the 20-item Problem Areas In Diabetes scale
At-home measurements of fasting glucose
Weekly average for each time point
In-clinic measurements of fasting glucose
Discrete lab measurement
Usability
Device-related and -unrelated adverse events

Full Information

First Posted
December 28, 2011
Last Updated
March 1, 2013
Sponsor
Proteus Digital Health, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01503008
Brief Title
Proteus Sustained Behavior Change Study
Official Title
Proteus Sustained Behavior Change Study
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Withdrawn
Study Start Date
February 2012 (undefined)
Primary Completion Date
August 2012 (Anticipated)
Study Completion Date
August 2012 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Proteus Digital Health, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The study will test whether the Proteus Sustained Behavior Change (SBC) System will help Type 2 diabetics feel more able to perform self-care activities, feel less distressed about diabetes, and reduce mean fasting blood glucose levels. The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Sustained Behavior Change system support
Arm Type
Experimental
Arm Title
Control
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Proteus Sustained Behavior Change system
Intervention Description
The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
Intervention Type
Drug
Intervention Name(s)
Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
Intervention Description
Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
Primary Outcome Measure Information:
Title
Self-efficacy
Description
As measured by the 13-item self-efficacy expectancies and outcomes expectancies sub-scale of the Multidimensional Diabetes Questionnaire
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Perceived effectiveness of caregiver support
Description
As measured by the 12-item positive reinforcing behaviors and misguided support sub-scale of the Multidimensional Diabetes Questionnaire
Time Frame
3 months
Title
Diabetes-related distress
Description
As measured by the 20-item Problem Areas In Diabetes scale
Time Frame
3 months
Title
At-home measurements of fasting glucose
Description
Weekly average for each time point
Time Frame
1, 6, 12 weeks
Title
In-clinic measurements of fasting glucose
Description
Discrete lab measurement
Time Frame
0, 6, 12 weeks
Title
Usability
Time Frame
3 months
Title
Device-related and -unrelated adverse events
Time Frame
Up to 4 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Self-reported diagnosis of Type 2 Diabetes Mellitus within the past 2-12 months Hemoglobin A1c ≥7.5 and ≤11, obtained with the point-of-care HbA1c diagnostic device during the enrollment visit Self-reported current use of metformin for Type 2 diabetes Male or female ≥ 18 Outpatient Self-reported capacity to perform "moderate" exercise, as specified by in the 2010 joint American College of Sports Medicine/American Diabetes Association guidelines Designation of one caregiver to be involved in the study for its entire duration. A caregiver can be a relative, friend, or trained or untrained hired individual. Self-reported mobile phone reception at home and/or at work Willingness to adhere to study procedures, including troubleshooting of the Raisin System by a third-party if needed. The third party will be blinded to any personal subject identifiers. Capacity to read and speak English proficiently, as judged by the investigator during the screening interview Capacity to understand the instructions for the study, as judged by the investigator during the screening interview Exclusion Criteria: Self-reported treatment with metformin for less than 2 months at the time of screening Self-reported adverse reaction to metformin (e.g., ongoing nausea, vomiting, bloating, diarrhea) or to other concomitant medications being administered at the time of screening Self-reported use of injectable hypoglycemic agents, such as insulin, exenatide, liraglutide or pramlintide Physical or medical condition that could prevent safe participation in moderate levels of physical activity, as surveyed by the Physical Activity Readiness Questionnaire (PAR-Q) and interpreted by the investigator Inability to use a mobile phone (e.g., to find icons or to open and to read a SMS), or inability to operate the approved glucometer that will be provided for use in the study Self-reported current (i.e., in the last 12 months) alcohol or drug abuse (including, but not limited, to use of marijuana) Positive urine pregnancy test for women Women of child bearing potential who are not using a medically accepted means of contraception. Accepted means of contraception include oral contraceptive or implant, condom, diaphragm, spermicide, intrauterine device, tubal ligation, or partner with vasectomy Self-reported history of myocardial infarction within past 60 days Self-reported history of cerebral vascular accident within past 60 days Self-reported history of skin sensitivity to adhesive medical tape or metals Self-reported history of acute or chronic dermatitis, excluding atopic dermatitis Self-reported allergies that could preclude safe participation in the study Current participation in another clinical study, or participation in a clinical study in the past 30 days during which an investigational device or drug was used Any condition that, in the investigator's opinion, would preclude the subject's being able to meet all of the protocol requirements, or would compromise the subject's safety during participation in the study Presence of cognitive impairment, as judged by the investigator during the screening interview Inability to provide informed consent for any reason
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kamal Jethwani, MD
Organizational Affiliation
Center for Connected Health, Partners Healthcare
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michael J Coons, PhD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Bonnie Spring, PhD
Organizational Affiliation
Northwestern University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Center for Connected Health, Partners Healthcare
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Proteus Sustained Behavior Change Study

We'll reach out to this number within 24 hrs